Biocytogen-B (02315) rose more than 6% again, reaching HK$63.3 at the time of writing, with a trading volume of HK$56.0117 million. The increase follows the announcement of a formal strategic collaboration agreement with SIHUAN PHARM. The partnership will leverage Biocytogen's leading fully human antibody development platform and SIHUAN PHARM's extensive experience in drug development, production, and commercialization. The companies will collaborate on innovative drug research in multiple disease areas, including weight loss, aiming to combine strengths and resources for a long-term, stable relationship. The first project under this agreement will focus on SIHUAN PHARM's next-generation weight-loss drug candidate. SIHUAN PHARM has expressed strong confidence in Biocytogen's technological capabilities. Biocytogen will contribute its self-developed model animal and efficacy platforms, fully human antibody discovery platform, and AI-powered antibody drug development platform to support the collaboration. By integrating both parties' capabilities in innovation and industrial application, the partnership is expected to enhance the efficiency of innovative drug development.